Managed Healthcare Executive

FDA approves Eylea HD for retinal vein occlusion

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Healio

Pharmacotherapy sets new standard of care for retinal vein occlusion, but questions remain

Please provide your email address to receive an email when new articles are posted on . For the last 2 decades, there has been little debate about the preferred treatment of retinal vein occlusion.
Healio

FDA designates recall of intra-aortic occlusion device as class 1

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has designated Edwards Lifesciences’ product ...
TCTMD

TCT 778: Iatrogenic left main-stem dissection and occlusion class (F) extending retrogradely involving ascending aorta after percutaneous coronary intervention: a case report

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...